


## RhIR antagonist 1

Cat. No.:	HY-131337
CAS No.:	2614320-29-3
Molecular Formula:	C <sub>12</sub> H <sub>10</sub> F <sub>2</sub> O
Molecular Weight:	208.2
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	RhIR antagonist 1 is a potent RhIR antagonist with an IC <sub>50</sub> of 26 μM. RhIR antagonist 1 displays selective RhIR antagonism over LasR and PqsR, strong inhibition of biofilm formation in static and dynamic settings, and reduces production of virulence factors such as rhamnolipid and pyocyanin in <i>P. aeruginosa</i> . RhIR antagonist 1 can be utilized for developing QS-modulating molecules in the control of <i>P. aeruginosa</i> infections <sup>[1]</sup> . RhIR antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.
<b>In Vitro</b>	RhIR antagonist 1 (compound 30) (10 μM) inhibits <i>P. aeruginosa</i> biofilm formation by 74% and decreases the amount of carbohydrate and protein by 39 and 72%, respectively. RhIR antagonist 1 reduces significantly rhamnolipid production by <i>P. aeruginosa</i> at 10 and 100 μM concentrations. RhIR antagonist 1 (0-10 μM; 24 hours) down-regulates rhlA expression of biofilm cells. RhIR antagonist 1 could inhibit <i>P. aeruginosa</i> biofilm formation and virulence factor production by down-regulating the rhlA expression of <i>PP. aeruginosa</i> <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Larvae injected with <i>P. aeruginosa</i> started to die in initial incubation time and 70% of them died at the end of the 20-day incubation period. The survival rate of RhIR antagonist 1 (0-10 μM)-treated larvae is greatly improved, with approximately 80% larvae surviving at the end of the incubation period. In addition, larvae injected with rhIR mutants of <i>P. aeruginosa</i> shows a 90% survival rate after 20 days <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Nam S, et al. Discovery and characterization of pure RhIR antagonists against *Pseudomonas aeruginosa* infections [published online ahead of print, 2020 Jul 22]. *J Med Chem.* 2020;10.1021/acs.jmedchem.0c00630.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA